The scientists behind the pivotal DECIDE study recently published a new post-hoc analysis to demonstrate a notably higher number of people who receive Zinbryta treatments and show no evidence of disease activity (NEDA) over patients with Avonex intramuscular injections.
Results of the study support the promising outcomes of Zinbryta with NEDA status. Further interim data taken from the long-term extension study (EXTEND) are expected to confirm Zinbryta's effectiveness for clinically meaningful multiple sclerosis (MS) disease activity measures.
“Zinbryta is a new, once-monthly, self-administered, subcutaneous treatment option for people living with relapsing forms of MS, including those whose disease activity has been insufficiently controlled by their prior therapy,” Dr. Ralph Kern, senior vice president of Worldwide Medical, Biogen, said. “These data continue to reinforce Zinbryta's robust efficacy in reducing MS relapse rates, disability progression and brain lesion development, and help further define its long-term safety profile. Zinbryta is now available in the United States and Germany, and will soon be introduced in additional European countries.”
Scientists are optimistic about the positive news for the new treatment approach.
“Zinbryta had previously demonstrated significant efficacy in helping patients achieve NEDA status compared to Avonex at week 96,” Professor Gavin Giovannoni, chair of neurology at the Blizard Institute, Barts and The London School of Medicine and Dentistry, said. “This new analysis looked at Zinbryta's effectiveness on NEDA both during the first six months and the following 18 months of treatment to take into account the potential impact of pre-existing disease activity, and found the efficacy of Zinbryta on NEDA to be more evident at the end of the evaluation period.”
